Completed PHASE2 INTERVENTIONAL 1-arm NCT03603249

Trimetazidine as an Adjunct to Enhance Clopidogrel Response. (TRACER)

Trimetazidine as an Adjunct to Enhance Clopidogrel Response: The TRACER Study.

Sponsor: The University of The West Indies

Conditions Platelet Dysfunction Due to Drugs

Updated 6 times since 2018 Last updated: Nov 28, 2019 Started: Jul 1, 2018 Primary completion: Apr 1, 2019 Completion: Apr 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Platelet Dysfunction Due to Drugs and is currently completed. The University of The West Indies leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2018 — Jan 2020 [monthly]

Active Not Recruiting PHASE2

▶ Show 1 earlier version

Aug 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of The West Indies

Data source: The University of The West Indies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Augustine, Trinidad and Tobago